Resultados de búsqueda - Colleoni, M.

Limitar resultados
Exportar CSV
  1. 1

    Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian...

    Artículo | por Ribi, K; Luo, WX; Bernhard, J; Francis, PA; Burstein, HJ; Ciruelos, E; Bellet, M; Pavesi, L; Lluch, A; Visini, M; Parmar, V; Tondini, C; Kerbrat, P; Perello, A; Neven, P; Torres, R; Lombardi, D; Puglisi, F; Karlsson, P; Ruhstaller, T; Colleoni, M; Coates, AS; Goldhirsch, A; Price, KN; Gelber, RD; Regan, MM; Fleming, GF | Publicado 2016 |
    Otros Autores: “…Colleoni, M…”
  2. 2

    Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer

    Artículo | por Balko JM; Licata L; Wang XQ; Dugo M; Huang CS; Egle D; Bermejo B; Zamagni C; Thill M; Anton A; Russo S; Sevillano E; Ciruelos EM; Greil R; Semiglazov V; Colleoni M; Kelly CM; Mariani G; Del Mastro L; Zambelli S; Viale G; Callari M; Pusztai L; Gianni L; Ali HR; Bianchini G | Publicado 2025 |
    Otros Autores: “…Colleoni M…”
  3. 3

    Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.

    Artículo | por Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V | Publicado 2019 |
    Otros Autores: “…Colleoni M…”
  4. 4

    Spatial predictors of immunotherapy response in triple-negative breast cancer

    Artículo | por Wang, XQ; Danenberg, E; Huang, CS; Egle, D; Callari, M; Bermejo, B; Dugo, M; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Russo, S; Ciruelos, EM; Greil, R; Gyorffy, B; Semiglazov, V; Colleoni, M; Kelly, CM; Mariani, G; Del Mastro, L; Biasi, O; Seitz, RS; Valagussa, P; Viale, G; Gianni, L; Bianchini, G; Ali, HR | Publicado 2023 |
    Otros Autores: “…Colleoni, M…”
  5. 5

    Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangel...

    Artículo | por Gianni L; Huang CS; Egle D; Bermejo B; Zamagni C; Thill M; Anton A; Zambelli S; Bianchini G; Russo S; Ciruelos EM; Greil R; Semiglazov V; Colleoni M; Kelly C; Mariani G; Del Mastro L; Maffeis I; Valagussa P; Viale G | Publicado 2022 |
    Otros Autores: “…Colleoni M…”
  6. 6

    Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast C...

    Artículo | por Llombart-Cussac A; Harper-Wynne C; Perelló A; Hennequin A; Fernández-Ortega A; Colleoni M; Marín S; Quiroga V; Medioni J; Iranzo V; Wheatley D; Del Barco Berrón S; Antón A; Dobi E; Ruiz-Borrego M; Alcalá-López D; Pérez-Escuredo J; Antonarelli G; Sampayo-Cordero M; Pérez-García JM; Cortés J | Publicado 2025 |
    Otros Autores: “…Colleoni M…”
  7. 7

    Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Allia...

    Artículo | por de, Azambuja, E; Piccart-Gebhart, M; Fielding, S; Townend, J; Hillman, DW; Colleoni, M; Roylance, R; Kelly, CM; Lombard, J; El-Abed, S; Choudhury, A; Korde, L; Vicente, M; Chumsri, S; Rodeheffer, R; Ellard, SL; Wolff, AC; Holtschmidt, J; Lang, I; Untch, M; Boyle, F; Xu, B; Werutsky, G; Tujakowski, J; Huang, C-S; Baruch, NB; Bliss, J; Ferro, A; Gralow, J; Kim, S-B; Kroep, JR; Krop, I; Kuemmel, S; McConnell, R; Moscetti, L; Knop, AS; van, Duijnhoven, F; Gomez, H; Cameron, D; Di, Cosimo, S; Gelber, RD; Moreno-Aspitia, A | Publicado 2024 |
    Otros Autores: “…Colleoni, M…”
  8. 8

    The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

    Artículo | por Dugo M; Huang CS; Egle D; Bermejo B; Zamagni C; Seitz RS; Nielsen TJ; Thill M; Antón-Torres A; Russo S; Ciruelos EM; Schweitzer BL; Ross DT; Galbardi B; Greil R; Semiglazov V; Gyorffy B; Colleoni M; Kelly CM; Mariani G; Del Mastro L; Blasi O; Callari M; Pusztai L; Valagussa P; Viale G; Gianni L; Bianchini G | Publicado 2024 |
    Otros Autores: “…Colleoni M…”
  9. 9

    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis...

    Artículo | por Regan, MM; Walley, BA; Francis, PA; Fleming, GF; Láng, I; Gómez, HL; Colleoni, M; Tondini, C; Pinotti, G; Salim, M; Spazzapan, S; Parmar, V; Ruhstaller, T; Abdi, EA; Gelber, RD; Coates, AS; Goldhirsch, A; Pagani, O | Publicado 2017 |
    Otros Autores: “…Colleoni, M…”
  10. 10

    Optimal [<SUP>18</SUP>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the...

    Artículo | por Gebhart, G; Keyaerts, M; Guiot, T; Flamen, P; Ruiz-Borrego, M; Stradella, A; Bermejo, B; Escriva-de-Romani, S; Martínez, LC; Ribelles, N; Fernandez-Abad, M; Albacar, C; Colleoni, M; Garrigos, L; de Frutos, MA; Dalenc, F; Prat, A; Marmé, F; Schmid, P; Kerrou, K; Braga, S; Gener, P; Sampayo-Cordero, M; Cortés, J; Pérez-García, JM; Llombart-Cussac, A | Publicado 2024 |
    Otros Autores: “…Colleoni, M…”

Herramientas de búsqueda: